Scientific Highlights

Datum
3 juin 2021
SARS-CoV-2_orf9b

Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus-host interactions

In a study published in Nature Communications, researchers at the NHC Key Laboratory of Systems Biology of Pathogens in Beijing, China, in collaboration with the Paul Scherrer Institut characterize the interactions of SARS-CoV-2 orf9b and human TOM70 biochemically, and they determine the 2.2 Å crystal structure of the TOM70 cytosolic domain with a bound SARS-CoV-2 orf9b peptide.

En savoir plus
11 mai 2021
Teaser Remdesivir

How remdesivir works against the coronavirus

Human Health Medical Science Research on Covid-19

Researchers at Goethe University Frankfurt, in cooperation with the PSI have probably discovered another, previously unknown mechanism of action of the antiviral remdesivir.

En savoir plus
10 mai 2021
darobactin

Combating antimicrobial resistance

In a study addressing the global health threat of drug resistance, researchers at the Biozentrum, University of Basel, have revealed how a new antibiotic, Darobactin, binds to the external membrane of gram-negative bacteria.

En savoir plus
30 juillet 2020
Dr. May Elizabeth Sharpe

Covid-19 research: Anti-viral strategy with double effect

Research Using Synchrotron Light Biology Human Health Research on Covid-19

Frankfurt scientists identify a possible weakness of the SARS-CoV-2 virus. They carried out part of their measurements at PSI's Swiss Light Source SLS. The research results are published this week in the scientific journal Nature.

En savoir plus
15 mai 2020
Dikic lab

First MX results of the priority COVID-19 call

The Dikic group at the Goethe University in Frankfurt am Main, Germany has published the first results following the opening of the "PRIORITY COVID-19 Call” at SLS. 

En savoir plus
12 novembre 2018
Picture3.jpg

A crystal-clear picture

Fast and accurate data collection for macromolecular crystallography using the JUNGFRAU detector.

En savoir plus
12 août 2018

First serial femtosecond crystallography (SFX) pilot user experiment at SwissFEL

On the 7th to 12th of August 2018, a collaborative group of scientists from the Paul Scherrer Institute and members of the LeadXpro and Heptares pharmaceutical companies led by Karol Nass (PSI macromolecular crystallography MX-SLS group) performed the first serial femtosecond crystallography (SFX) pilot user experiment at the SwissFEL X-ray free electron laser (XFEL).

En savoir plus